Gabapentin Capsule
Product Images NDC 68788-8199

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-8199). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Capsules 100mg (6ecf5114 2ddc 4025 A36d 1884702dc22a 00)

Gabapentin Capsules 100mg packaging label from Preferred Pharmaceuticals Inc. It is labeled as generic for Neurontin and indicates each capsule contains 100mg gabapentin. The label includes storage instructions, barcode, and bilingual dosage directions in English and Spanish. Manufacturer ACI Healthcare USA, Inc. is noted, along with placeholders for lot, batch, and expiration information.*

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustrated formula depicting the calculation of creatinine clearance (CLCr), including variables for age, weight, serum creatinine, and an adjustment factor for female patients.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure diagram of gabapentin showing a cyclohexane ring attached to a carbon atom bonded to both an amino group (CH2NH2) and a carboxylic acid group (CH2CO2H).*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph showing mean pain scores over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks including a 4-week dose titration period and 4-week fixed dose period. The y-axis indicates mean pain score ranging from 0 to 10. Gabapentin line shows a decrease in pain score over time, while placebo remains relatively stable.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

Line graph depicting mean pain score over 7 weeks during a 3-week dose titration period followed by a 4-week fixed dose period. The graph compares placebo and two Gabapentin dose groups (1800 mg/day and 2400 mg/day), showing changes in mean pain scores at weekly intervals from baseline to week 7.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

This bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' compares response rates between placebo (PBO) and gabapentin (GBP) at different doses in two studies. Study 1 shows 12% response for placebo and 29% for gabapentin 3600 mg, Study 2 shows 14% for placebo, 32% for gabapentin 1800 mg, and 34% for gabapentin 2400 mg. Statistical significance is marked with p-values below 0.01 and 0.001.*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing difference percentages relative to daily doses of 600 to 1800 mg gabapentin across three studies labeled A, B, and C. Data points for each study are distinguished by different square shading and positioned to show variance in difference percentages by dose level.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.